Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

The Potential for US Patent Reform (<i>The Center for Biosimilars</i>)

main

08_21 Press Post_The Potential for US Patent

Press Post: The Potential for US Patent Reform (The Center for Biosimilars)

The Potential for US Patent Reform (The Center for Biosimilars)

Related Content

Xbrane Biopharma AB and JOINN Biologics US Inc. Partner to Develop Xdarzane

FDA Expands TOFIDENCE® (tocilizumab-bavi) Label to Include CRS and COVID-19

Teva Launches AHZANTIVE® Aflibercept Biosimilar in Europe

SEC Proposal Could Eliminate Baby Shelf Restrictions and Expand ATM Program Access For Smaller Companies

Delaware is Enforcing Its Principal Place of Business Requirement: An Inaccurate Address Can Block Good Standing Certificates

Royalty Monetization in an Era of Drug Pricing Pressure: How the IRA is Affecting Royalty Monetizations

Incyte to Acquire Vega Therapeutics, Adding Phase 3 Bleeding Disorder Asset

FDA Approves Lupin’s Ranibizumab Biosimilar

Goodwin Guides Oblenio Bio on Closing $62 Million Series B

Goodwin Advises Ollin Biosciences on Oversubscribed $330 Million Series B Financing

Goodwin Guides Absci on Pricing of $100 Million Underwritten Offering

Goodwin Guides Triveni Bio on $65 Million Series C Financing

Goodwin Advises Kardigan on Closing of $460 Million Upsized Initial Public Offering

Goodwin Guides Tango Therapeutics in Upsized $690 Million Public Offering

Goodwin Guides City Therapeutics on $99.5 Million Series B Financing

Goodwin Advises Incyte in Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Incyte’s Hematology Portfolio into Bleeding Disorders

Life Sciences

Patent Litigation

Life Sciences Patent Prosecution & Counseling

Patent Prosecution & Counseling

Patent Trial & Appeal Board

Intellectual Property

Hatch-Waxman, Biologics and Biosimilars Litigation

Litigation